Inherited predisposition to myeloproliferative neoplasms

Therapeutic Advances in Hematology

Volumn 4, Issue 4, 2013, Pages 237-253

  Jones, Amy V ^a   Cross, Nicholas C P ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

familial myeloproliferative neoplasms; inherited predisposition; JAK2 46 1 haplotype; Myeloproliferative neoplasms

Indexed keywords

CBL PROTEIN; DNA METHYLTRANSFERASE 3A; ERYTHROPOIETIN RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 1; GLUCOCORTICOID RECEPTOR BETA; HYPOXIA INDUCIBLE FACTOR 1ALPHA; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; JANUS KINASE 2; STAT1 PROTEIN; STAT5 PROTEIN; STEM CELL FACTOR RECEPTOR; TELOMERASE REVERSE TRANSCRIPTASE; THROMBOPOIETIN; TRANSCRIPTION FACTOR EZH2;

ASXL 1 GENE; BONE MARROW CELL; CELL PROLIFERATION; CLONAL EVOLUTION; CYTOGENETICS; ERYTHROCYTOSIS; EXOME; GENE; GENE FREQUENCY; GENE MUTATION; GENETIC ASSOCIATION; GENETIC EPIDEMIOLOGY; GENETIC HETEROGENEITY; GENETIC PREDISPOSITION; GENETIC VARIABILITY; GENOME; HAPLOTYPE; HERITABILITY; HUMAN; INHERITANCE; MPL GENE; MYELOID LEUKEMIA; MYELOID PROGENITOR CELL; MYELOPROLIFERATIVE NEOPLASM; OXYGEN SENSING; PATHOGENESIS; PHENOTYPIC VARIATION; PRIORITY JOURNAL; REVIEW; SH2B3 GENE; TET2 GENE; THROMBOCYTOSIS;

EID: 84993813872     PISSN: 20406207     EISSN: 20406215     Source Type: Journal    
DOI: 10.1177/2040620713489144     Document Type: Article

References (152)

1. Abdel-Wahab O. Pardanani A. Rampal R. Lasho T. Levine R. Tefferi A. (2011) DNMT3A mutational analysis in primary myelofibrosis, chronic myelomonocytic leukemia and advanced phases of myeloproliferative neoplasms. Leukemia 25: 1219–1220.
2. Aguiar R. Chase A. Coulthard S. Macdonald D. Carapeti M. Reiter A. et al. (1997) Abnormalities of chromosome band 8p11 in leukemia: two clinical syndromes can be distinguished on the basis of MOZ involvement. Blood 90: 3130–3135.
3. Aksoy M. (1980) Malignancies due to occupational exposure to benzene. Haematologica 65.
4. Al-Sheikh M. Mazurier E. Gardie B. Casadevall N. Galacteros F. Goossens M. et al. (2008) A study of 36 unrelated cases with pure erythrocytosis revealed three new mutations in the erythropoietin receptor gene. Haematologica 93: 1072–1075.
5. Albiero E. Ruggeri M. Fortuna S. Finotto S. Bernardi M. Madeo D. et al. (2012) Isolated erythrocytosis: study of 67 patients and identification of three novel germ-line mutations in the prolyl hydroxylase domain protein 2 (PHD2) gene. Haematologica 97: 123–127.
6. Alvarez-Larran A. Angona A. Martinez-Aviles L. Bellosillo B. Besses C. (2012) Influence of JAK2 46 / 1 haplotype in the natural evolution of JAK2V617F allele burden in patients with myeloproliferative neoplasms. Leuk Res 36: 324–326.
7. Anderson C. Boucher G. Lees C. Franke A. D'Amato M. Taylor K. et al. (2011 a) Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet 43: 246–252.
8. Anderson L. Duncombe A. Hughes M. Mills M. Wilson J. McMullin M. (2011 b) Environmental, lifestyle, and familial / ethnic factors associated with myeloproliferative neoplasms. Am J Hematol 87: 175–182.
9. Andrikovics H. Nahajevszky S. Koszarska M. Meggyesi N. Bors A. Halm G. et al. (2010) JAK2 46 / 1 haplotype analysis in myeloproliferative neoplasms and acute myeloid leukemia. Leukemia 24: 1809–1813.
10. Ang S. Chen H. Hirota K. Gordeuk V. Jelinek J. Guan Y. et al. (2002) Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia. Nat Genet 32: 614–621.
11. Assumpcao J. Seidinger A. Mastellaro M. Ribeiro R. Zambetti G. Ganti R. et al. (2008) Association of the germline TP 53 R337H mutation with breast cancer in southern Brazil. BMC Cancer 8: 357.
12. Bacher U. Haferlach T. Kern W. Haferlach C. Schnittger S. (2007) A comparative study of molecular mutations in 381 patients with myelodysplastic syndrome and in 4130 patients with acute myeloid leukemia. Haematologica 92: 744–752.
13. Barosi G. Magrini U. Gale R. (2010) Does auto-immunity contribute to anemia in myeloproliferative neoplasms (MPN)-associated myelofibrosis? Leuk Res 34: 1119–1120.
14. Barrett J. Hansoul S. Nicolae D. Cho J. Duerr R. Rioux J. et al. (2008) Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet 40: 955–962.
15. Baxter E. Scott L. Campbell P. East C. Fourouclas N. Swanton S. et al. (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365: 1054–1061.
16. Bellanne-Chantelot C. Chaumarel I. Labopin M. Bellanger F. Barbu V. de Toma C. et al. (2006) Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders. Blood 108: 346–352.
17. Bento M. Chang K. Guan Y. Liu E. Caldas G. Gatti R. et al. (2005) Congenital polycythemia with homozygous and heterozygous mutations of von Hippel–Lindau gene: five new Caucasian patients. Haematologica 90: 128–129.
18. Bercovich D. Ganmore I. Scott L. Wainreb G. Birger Y. Elimelech A. et al. (2008) Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome. Lancet 372: 1484–1492.
19. Bernardini P. Giannandrea F. Voso M. Sica S. (2005) [Myeloproliferative disorders due to the use of gasoline as a solvent: report of three cases]. Med Lav 96: 119–125.
20. Campbell P. Green A. (2006) The myeloproliferative disorders. N Engl J Med 355: 2452–2466.
21. Carbuccia N. Murati A. Trouplin V. Brecqueville M. Adelaide J. Rey J. et al. (2009) Mutations of ASXL 1 gene in myeloproliferative neoplasms. Leukemia 23: 2183–2186.
22. Cario H. Schwarz K. Jorch N. Kyank U. Petrides P. Schneider D. et al. (2005) Mutations in the von Hippel-Lindau (VHL) tumor suppressor gene and VHL-haplotype analysis in patients with presumable congenital erythrocytosis. Haematologica 90: 19–24.
23. Chaiter Y. Brenner B. Aghai E. Tatarsky I. (1992) High incidence of myeloproliferative disorders in Ashkenazi Jews in northern Israel. Leuk Lymphoma 7: 251–255.
24. Chen E. Beer P. Godfrey A. Ortmann C. Li J. Costa-Pereira A. et al. (2010) Distinct clinical phenotypes associated with JAK2V617F reflect differential STAT 1 signaling. Cancer Cell 18: 524–535.
25. Cools J. de Angelo D. Gotlib J. Stover E. Legare R. Cortes J. et al. (2003) A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 348: 1201–1214.
26. Cross N. (2011) Genetic and epigenetic complexity in myeloproliferative neoplasms. Hematology Am Soc Hematol Educ Program 2011: 208–214.
27. Cross N. Reiter A. (2008) Fibroblast growth factor receptor and platelet-derived growth factor receptor abnormalities in eosinophilic myeloproliferative disorders. Acta Haematologica 119: 199–206.
28. de la Chapelle A. Traskelin A. Juvonen E. (1993) Truncated erythropoietin receptor causes dominantly inherited benign human erythrocytosis. Proc Natl Acad Sci U S A 90: 4495–4499.
29. Delhommeau F. Dupont S. Della Valle V. James C. Trannoy S. Masse A. et al. (2009) Mutation in TET 2 in myeloid cancers. N Engl J Med 360: 2289–2301.
30. Ding J. Komatsu H. Wakita A. Kato-Uranishi M. Ito M. Satoh A. et al. (2004) Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin. Blood 103: 4198–4200.
31. Ding Y. Harada Y. Imagawa J. Kimura A. Harada H. (2009) AML1/RUNX1 point mutation possibly promotes leukemic transformation in myeloproliferative neoplasms. Blood 114: 5201–5205.
32. Dusa A. Staerk J. Elliott J. Pecquet C. Poirel H. Johnston J. et al. (2008) Substitution of pseudokinase domain residue Val-617 by large non-polar amino acids causes activation of JAK2. J Biol Chem 283: 12941–12948.
33. El-Harith E. Roesl C. Ballmaier M. Germeshausen M. Frye-Boukhriss H. von Neuhoff N. et al. (2009) Familial thrombocytosis caused by the novel germ-line mutation p.Pro106Leu in the MPL gene. Br J Haematol 144: 185–194.
34. Ellinghaus D. Ellinghaus E. Nair R. Stuart P. Esko T. Metspalu A. et al. (2012) Combined analysis of genome-wide association studies for Crohn disease and psoriasis identifies seven shared susceptibility loci. Am J Hum Genet 90: 636–647.
35. Ernst T. Chase A. Score J. Hidalgo-Curtis C. Bryant C. Jones A. et al. (2010) Inactivating mutations of the histone methyltransferase gene EZH 2 in myeloid disorders. Nat Genet 42: 722–726.
36. Etheridge L. Corbo L. Kaushansky K. Chan E. Hitchcock I. (2011) A novel activating JAK2 mutation, JAK2R564Q, causes familial essential thrombocytosis (fET) via mechanisms distinct from JAK2V617F. ASH Annual Meeting Abstracts 118 (21): 123.
37. Falini B. Mecucci C. Tiacci E. Alcalay M. Rosati R. Pasqualucci L. et al. (2005) Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 352: 254–266.
38. Figueroa M. Abdel-Wahab O. Lu C. Ward P. Patel J. Shih A. et al. (2010) Leukemic IDH 1 and IDH 2 mutations result in a hypermethylation phenotype, disrupt TET 2 function, and impair hematopoietic differentiation. Cancer Cell 18: 553–567.
39. Frederiksen H. Farkas D. Christiansen C. Hasselbalch H. Sorensen H. (2011) Chronic myeloproliferative neoplasms and subsequent cancer risk: a Danish population-based cohort study. Blood 118: 6515–6520.
40. Furitsu T. Tsujimura T. Tono T. Ikeda H. Kitayama H. Koshimizu U. et al. (1993) Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. J Clin Invest 92: 1736–1744.
41. Furlow P. Percy M. Sutherland S. Bierl C. McMullin M. Master S. et al. (2009) Erythrocytosis-associated HIF-2alpha mutations demonstrate a critical role for residues C-terminal to the hydroxylacceptor proline. J Biol Chem 284: 9050–9058.
42. Gale D. Harten S. Reid C. Tuddenham E. Maxwell P. (2008) Autosomal dominant erythrocytosis and pulmonary arterial hypertension associated with an activating HIF 2 alpha mutation. Blood 112: 919–921.
43. Ghilardi N. Skoda R. (1999) A single-base deletion in the thrombopoietin (TPO) gene causes familial essential thrombocythemia through a mechanism of more efficient translation of TPO mRNA. Blood 94: 1480–1482.
44. Ghilardi N. Wiestner A. Kikuchi M. Ohsaka A. Skoda R. (1999) Hereditary thrombocythaemia in a Japanese family is caused by a novel point mutation in the thrombopoietin gene. Br J Haematol 107: 310–316.
45. Gieger C. Radhakrishnan A. Cvejic A. Tang W. Porcu E. Pistis G. et al. (2011) New gene functions in megakaryopoiesis and platelet formation. Nature 480: 201–208.
46. Godfrey A. Chen E. Pagano F. Ortmann C. Silber Y. Bellosillo B. et al. (2012) JAK2V617F homozygosity arises commonly and recurrently in PV and ET, but PV is characterized by expansion of a dominant homozygous subclone. Blood 120: 2704–2707.
47. Goldin L. Kristinsson S. Liang X. Derolf A. Landgren O. Bjorkholm M. (2012) Familial aggregation of acute myeloid leukemia and myelodysplastic syndromes. J Clin Oncol 30: 179–183.
48. Gordeuk V. Stockton D. Prchal J. (2005) Congenital polycythemias/erythrocytoses. Haematologica 90: 109–116.
49. Grand F. Hidalgo-Curtis C. Ernst T. Zoi K. Zoi C. McGuire C. et al. (2009) Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms. Blood 113: 6182–6192.
50. Green A. Beer P. (2010) Somatic mutations of IDH 1 and IDH 2 in the leukemic transformation of myeloproliferative neoplasms. N Engl J Med 362: 369–370.
51. Guglielmelli P. Biamonte F. Spolverini A. Pieri L. Isgro A. Antonioli E. et al. (2010) Frequency and clinical correlates of JAK2 46 / 1 (GGCC) haplotype in primary myelofibrosis. Leukemia 24: 1533–1537.
52. Harutyunyan A. Gisslinger B. Klampfl T. Berg T. Bagienski K. Gisslinger H. et al. (2011 a) Rare germline variants in regions of loss of heterozygosity may influence clinical course of hematological malignancies. Leukemia 25: 1782–1784.
53. Harutyunyan A. Klampfl T. Cazzola M. Kralovics R. (2011 b) p 53 lesions in leukemic transformation. N Engl J Med 364: 488–490.
54. Hernandez-Boluda J. Pereira A. Cervantes F. Alvarez-Larran A. Collado M. Such E. et al. (2012) A polymorphism in the XPD gene predisposes to leukemic transformation and new nonmyeloid malignancies in essential thrombocythemia and polycythemia vera. Blood 119: 5221–5228.
55. Hertzberg L. Vendramini E. Ganmore I. Cazzaniga G. Schmitz M. Chalker J. et al. (2010) Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF 2 is associated with mutated JAK2: a report from the International BFM Study Group. Blood 115: 1006–1017.
56. Hinds D. Barnholt K. Zehnder J. Kiefer A. Do C. Eriksson N. et al. (2012) A germline variant in the TERT gene is a novel predisposition allele associated with myeloproliferative neoplasms. ASH Annual Meeting Abstracts 120 (21): 707.
57. Hoffman R. Rondelli D. (2007) Biology and treatment of primary myelofibrosis. Hematology Am Soc Hematol Educ Program 2007: 346–354.
58. Hultcrantz M. Kristinsson S. Andersson T. Landgren O. Eloranta S. Derolf A. et al. (2012) Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study. J Clin Oncol 30: 2995–3001.
59. Hussein K. Bock O. Seegers A. Flasshove M. Henneke F. Buesche G. et al. (2007) Myelofibrosis evolving during imatinib treatment of a chronic myeloproliferative disease with coexisting BCR-ABL translocation and JAK2V617F mutation. Blood 109: 4106–4107.
60. Jager R. Gisslinger H. Passamonti F. Rumi E. Berg T. Gisslinger B. et al. (2010) Deletions of the transcription factor Ikaros in myeloproliferative neoplasms. Leukemia 24: 1290–1298.
61. James C. Ugo V. Le Couedic J. Staerk J. Delhommeau F. Lacout C. et al. (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434: 1144–1148.
62. Johansson P. Kutti J. Andreasson B. Safai-Kutti S. Vilen L. Wedel H. et al. (2004) Trends in the incidence of chronic Philadelphia chromosome negative (Ph-) myeloproliferative disorders in the city of Goteborg, Sweden, during 1983–99. J Intern Med 256: 161–165.
63. Jones A. Campbell P. Beer P. Schnittger S. Vannucchi A. Zoi K. et al. (2010) The JAK2 46 / 1 haplotype predisposes to MPL-mutated myeloproliferative neoplasms. Blood 115: 4517–4523.
64. Jones A. Chase A. Silver R. Oscier D. Zoi K. Wang Y. et al. (2009) JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms. Nat Genet 41: 446–449.
65. Jones A. Cross N. (2010) No association between myeloproliferative neoplasms and the Crohn's disease-associated STAT 3 predisposition SNP rs744166. Haematologica 95: 1226–1227.
66. Kearney L. Gonzalez de Castro D. Yeung J. Procter J. Horsley S. Eguchi-Ishimae M. et al. (2009) Specific JAK2 mutation (JAK2R683) and multiple gene deletions in Down syndrome acute lymphoblastic leukemia. Blood 113: 646–648.
67. Kilpivaara O. Mukherjee S. Schram A. Wadleigh M. Mullally A. Ebert B. et al. (2009) A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms. Nat Genet 41: 455–459.
68. Kim W. Kaelin W. (2004) Role of VHL gene mutation in human cancer. J Clin Oncol 22: 4991–5004.
69. Klampfl T. Harutyunyan A. Berg T. Gisslinger B. Schalling M. Bagienski K. et al. (2011) Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression. Blood 118: 167–176.
70. Kondo T. Okabe M. Sanada M. Kurosawa M. Suzuki S. Kobayashi M. et al. (1998) Familial essential thrombocythemia associated with one-base deletion in the 5’-untranslated region of the thrombopoietin gene. Blood 92: 1091–1096.
71. Kouroupi E. Kiladjian J. Chomienne C. Dosquet C. Bellucci S. Valla D. et al. (2011) The JAK2 46 / 1 haplotype in splanchnic vein thrombosis. Blood 117: 5777–5778.
72. Kralovics R. Buser A. Teo S. Coers J. Tichelli A. van der Maas A. et al. (2003 a) Comparison of molecular markers in a cohort of patients with chronic myeloproliferative disorders. Blood 102: 1869–1871.
73. Kralovics R. Passamonti F. Buser A. Teo S. Tiedt R. Passweg J. et al. (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352: 1779–1790.
74. Kralovics R. Stockton D. Prchal J. (2003 b) Clonal hematopoiesis in familial polycythemia vera suggests the involvement of multiple mutational events in the early pathogenesis of the disease. Blood 102: 3793–3796.
75. Kristinsson S. Landgren O. Samuelsson J. Bjorkholm M. Goldin L. (2010) Autoimmunity and the risk of myeloproliferative neoplasms. Haematologica 95: 1216–1220.
76. Lacout C. Pisani D. Tulliez M. Gachelin F. Vainchenker W. Villeval J. (2006) JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood 108: 1652–1660.
77. Ladroue C. Hoogewijs D. Gad S. Carcenac R. Storti F. Barrois M. et al. (2012) Distinct deregulation of the hypoxia inducible factor by PHD 2 mutants identified in germline DNA of patients with polycythemia. Haematologica 97: 9–14.
78. Lambert J. Everington T. Linch D. Gale R. (2009) In essential thrombocythemia, multiple JAK2-V617F clones are present in most mutant-positive patients: a new disease paradigm. Blood 114: 3018–3023.
79. Landgren O. Goldin L. Kristinsson S. Helgadottir E. Samuelsson J. Bjorkholm M. (2008) Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24,577 first-degree relatives of 11,039 patients with myeloproliferative neoplasms in Sweden. Blood 112: 2199–2204.
80. Langemeijer S. Kuiper R. Berends M. Knops R. Aslanyan M. Massop M. et al. (2009) Acquired mutations in TET 2 are common in myelodysplastic syndromes. Nat Genet 41: 838–842.
81. Lasho T. Pardanani A. McClure R. Mesa R. Levine R. Gary Gilliland D. et al. (2006) Concurrent MPL 515 and JAK2V617F mutations in myelofibrosis: chronology of clonal emergence and changes in mutant allele burden over time. Br J Haematol 135: 683–687.
82. Lasho T. Tefferi A. Pardanani A. Finke C. Fink S. Caron A. et al. (2012) Differential distribution of CCDC 26 glioma-risk alleles in myeloid malignancies with mutant IDH 1 compared with their IDH2R140-mutated or IDH-unmutated counterparts. Leukemia 26: 1406–1407.
83. Lees C. Barrett J. Parkes M. Satsangi J. (2011) New IBD genetics: common pathways with other diseases. Gut 60: 1739–1753.
84. Levine R. Wadleigh M. Cools J. Ebert B. Wernig G. Huntly B. et al. (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7: 387–397.
85. Li S. Kralovics R. de Libero G. Theocharides A. Gisslinger H. Skoda R. (2008) Clonal heterogeneity in polycythemia vera patients with JAK2 exon12 and JAK2-V617F mutations. Blood 111: 3863–3866.
86. Liu K. Kralovics R. Rudzki Z. Grabowska B. Buser A. Olcaydu D. et al. (2008) A de novo splice donor mutation in the thrombopoietin gene causes hereditary thrombocythemia in a Polish family. Haematologica 93: 706–714.
87. Malcovati L. Papaemmanuil E. Bowen D.T. Boultwood J. Della Porta M. Pascutto C. et al. (2011) Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic / myeloproliferative neoplasms. Blood 118: 6239–6246.
88. Martini M. Teofili L. Cenci T. Giona F. Torti L. Rea M. et al. (2008) A novel heterozygous HIF2AM535I mutation reinforces the role of oxygen sensing pathway disturbances in the pathogenesis of familial erythrocytosis. Haematologica 93: 1068–1071.
89. McMullin M. (2010) HIF pathway mutations and erythrocytosis. Exp Rev Hematol 3: 93–101.
90. Mead A. Rugless M. Jacobsen S. Schuh A. (2012) Germline JAK2 mutation in a family with hereditary thrombocytosis. N Engl J Med 366: 967–969.
91. Meindl A. Hellebrand H. Wiek C. Erven V. Wappenschmidt B. Niederacher D. et al. (2010) Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. Nat Genet 42: 410–414.
92. Moliterno A. Williams D. Gutierrez-Alamillo L. Salvatori R. Ingersoll R. Spivak J. (2004) Mpl Baltimore: a thrombopoietin receptor polymorphism associated with thrombocytosis. Proc Natl Acad Sci U S A 101: 11444–11447.
93. Nahajevszky S. Andrikovics H. Batai A. Adam E. Bors A. Csomor J. et al. (2011) The prognostic impact of germline 46 / 1 haplotype of Janus kinase 2 in cytogenetically normal acute myeloid leukemia. Haematologica 96: 1613–1618.
94. Najean Y. Rain J. Billotey C. (1998) Epidemiological data in polycythaemia vera: a study of 842 cases. Hematol Cell Ther 40: 159–165.
95. Newton-Cheh C. Johnson T. Gateva V. Tobin M. Bochud M. Coin L. et al. (2009) Genome-wide association study identifies eight loci associated with blood pressure. Nat Genet 41: 666–676.
96. Nielsen C. Birgens H. Nordestgaard B. Bojesen S. (2013) Diagnostic value of JAK2V617F somatic mutation for myeloproliferative cancer in 49 488 individuals from the general population. Br J Haematol 160: 70–79.
97. Nielsen C. Birgens H. Nordestgaard B. Kjaer L. Bojesen S. (2011) The JAK2V617F somatic mutation, mortality and cancer risk in the general population. Haematologica 96: 450–453.
98. Nikoloski G. Langemeijer S. Kuiper R. Knops R. Massop M. Tonnissen E. et al. (2010) Somatic mutations of the histone methyltransferase gene EZH 2 in myelodysplastic syndromes. Nat Genet 42: 665–667.
99. Oh S. Simonds E. Jones C. Hale M. Goltsev Y. Gibbs K. Jr et al. (2010) Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms. Blood 116: 988–992.
100. Ohyashiki J. Yoneta M. Hisatomi H. Iwabuchi T. Umezu T. Ohyashiki K. (2012) The C allele of JAK2 rs4495487 is an additional candidate locus that contributes to myeloproliferative neoplasm predisposition in the Japanese population. BMC Med Genet 13: 6.
101. Olcaydu D. Harutyunyan A. Jager R. Berg T. Gisslinger B. Pabinger I. et al. (2009 a) A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms. Nat Genet 41: 450–454.
102. Olcaydu D. Skoda R. Looser R. Li S. Cazzola M. Pietra D. et al. (2009 b) The ‘GGCC’ haplotype of JAK2 confers susceptibility to JAK2 exon 12 mutation-positive polycythemia vera. Leukemia 23: 1924–1926.
103. Olcaydu D. Rumi E. Harutyunyan A. Passamonti F. Pietra D. Pascutto C. et al. (2011) The role of the JAK2 GGCC haplotype and the TET 2 gene in familial myeloproliferative neoplasms. Haematologica 96: 367–374.
104. Pardanani A. Fridley B. Lasho T. Gilliland D. Tefferi A. (2008) Host genetic variation contributes to phenotypic diversity in myeloproliferative disorders. Blood 111: 2785–2789.
105. Pardanani A. Lasho T. Finke C. Oh S. Gotlib J. Tefferi A. (2010 a) LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations. Leukemia 24: 1713–1718.
106. Pardanani A. Lasho T. Finke C. Gangat N. Wolanskyj A. Hanson C. et al. (2010 b) The JAK2 46 / 1 haplotype confers susceptibility to essential thrombocythemia regardless of JAK2V617F mutational status-clinical correlates in a study of 226 consecutive patients. Leukemia 24: 110–114.
107. Pastore Y. Jelinek J. Ang S. Guan Y. Liu E. Jedlickova K. et al. (2003) Mutations in the VHL gene in sporadic apparently congenital polycythemia. Blood 101: 1591–1595.
108. Percy M. Beer P. Campbell G. Dekker A. Green A. Oscier D. et al. (2008 a) Novel exon 12 mutations in the HIF2A gene associated with erythrocytosis. Blood 111: 5400–5402.
109. Percy M. Furlow P. Beer P. Lappin T. McMullin M. Lee F. (2007 a) A novel erythrocytosis-associated PHD 2 mutation suggests the location of a HIF binding groove. Blood 110: 2193–2196.
110. Percy M. Furlow P. Lucas G. Li X. Lappin T. McMullin M. et al. (2008 b) A gain-of-function mutation in the HIF2A gene in familial erythrocytosis. N Engl J Med 358: 162–168.
111. Percy M. Scott L. Erber W. Harrison C. Reilly J. Jones F. et al. (2007 b) The frequency of JAK2 exon 12 mutations in idiopathic erythrocytosis patients with low serum erythropoietin levels. Haematologica 92: 1607–1614.
112. Percy M. Zhao Q. Flores A. Harrison C. Lappin T. Maxwell P. et al. (2006) A family with erythrocytosis establishes a role for prolyl hydroxylase domain protein 2 in oxygen homeostasis. Proc Natl Acad Sci U S A 103: 654–659.
113. Piazza R. Valletta S. Winkelmann N. Redaelli S. Spinelli R. Pirola A. et al. (2012) Recurrent SETBP 1 mutations in atypical chronic myeloid leukemia. Nat Genet 45: 18–24.
114. Pietra D. Casetti I. Da Vià M. Elena C. Milanesi C. Rumi E. (2012) JAK2 GGCC haplotype in MPL mutated myeloproliferative neoplasms. Am J Hematol 87: 746–747.
115. Pikman Y. Lee B. Mercher T. McDowell E. Ebert B. Gozo M. et al. (2006) MPL W515L Is a Novel Somatic Activating Mutation in Myelofibrosis with Myeloid Metaplasia. PLoS Med 3 (7): e270.
116. Plo I. Nakatake M. Malivert L. de Villartay J. Giraudier S. Villeval J. et al. (2008) JAK2 stimulates homologous recombination and genetic instability: potential implication in the heterogeneity of myeloproliferative disorders. Blood 112: 1402–1412.
117. Poletto V. Rosti V. Villani L. Catarsi P. Carolei A. Campanelli R. et al. (2012) A3669G polymorphism of glucocorticoid receptor is a susceptibility allele for primary myelofibrosis and contributes to phenotypic diversity and blast transformation. Blood 120: 3112–3117.
118. Prchal J. (2005) Polycythemia vera and other primary polycythemias. Curr Opin Hematol 12: 112–116.
119. Prchal J. Crist W. Goldwasser E. Perrine G. Prchal J. (1985) Autosomal dominant polycythemia. Blood 66: 1208–1214.
120. Rondeau E. Solal-Celigny P. Dhermy D. Vroclans M. Brousse N. Bernard J. et al. (1983) Immune disorders in agnogenic myeloid metaplasia: relations to myelofibrosis. Br J Haematol 53: 467–475.
121. Rumi E. Harutyunyan A. Pietra D. (2012) A novel germline JAK2 mutation in familial thrombocytosis. Haematologica 97(Suppl. 1): 244.
122. Rumi E. Passamonti F. Della Porta M. Elena C. Arcaini L. Vanelli L. et al. (2007) Familial chronic myeloproliferative disorders: clinical phenotype and evidence of disease anticipation. J Clin Oncol 25: 5630–5635.
123. Rumi E. Passamonti F. Elena C. Pietra D. Arcaini L. Astori C. et al. (2011) Increased risk of lymphoid neoplasm in patients with myeloproliferative neoplasm: a study of 1,915 patients. Haematologica 96: 454–458.
124. Rumi E. Passamonti F. Pietra D. Della Porta M. Arcaini L. Boggi S. et al. (2006) JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders. Cancer 107: 2206–2211.
125. Saint-Martin C. Leroy G. Delhommeau F. Panelatti G. Dupont S. James C. et al. (2009) Analysis of the ten-eleven translocation 2 (TET2) gene in familial myeloproliferative neoplasms. Blood 114: 1628–1632.
126. Sanada M. Suzuki T. Shih L. Otsu M. Kato M. Yamazaki S. et al. (2009) Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms. Nature 460: 904–908.
127. Schaub F. Looser R. Li S. Hao-Shen H. Lehmann T. Tichelli A. et al. (2010) Clonal analysis of TET 2 and JAK2 mutations suggests that TET 2 can be a late event in the progression of myeloproliferative neoplasms. Blood 115: 2003–2007.
128. Score J. Cross N. (2012) Acquired uniparental disomy in myeloproliferative neoplasms. Hematol Oncol Clin North Am 26: 981–991.
129. Scott L. (2011) The JAK2 exon 12 mutations: a comprehensive review. Am J Hematol 86: 668–676.
130. Scott L. Scott M. Campbell P. Green A. (2006) Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia. Blood 108: 2435–2437.
131. Scott L. Tong W. Levine R. Scott M. Beer P. Stratton M. et al. (2007) JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 356: 459–468.
132. Sergeyeva A. Gordeuk V. Tokarev Y. Sokol L. Prchal J. Prchal J. (1997) Congenital polycythemia in Chuvashia. Blood 89: 2148–2154.
133. Skoda R. (2010) Hereditary myeloproliferative disorders. Haematologica 95: 6–8.
134. Smalberg J. Koehler E. Darwish Murad S. Plessier A. Seijo S. Trebicka J. et al. (2011) The JAK2 46 / 1 haplotype in Budd-Chiari syndrome and portal vein thrombosis. Blood 117: 3968–3973.
135. Stegelmann F. Bullinger L. Schlenk R. Paschka P. Griesshammer M. Blersch C. et al. (2011) DNMT3A mutations in myeloproliferative neoplasms. Leukemia 25: 1217–1219.
136. Tefferi A. Lasho T. Abdel-Wahab O. Guglielmelli P. Patel J. Caramazza D. et al. (2010 a) IDH 1 and IDH 2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. Leukemia 24: 1302–1309.
137. Tefferi A. Lasho T. Patnaik M. Finke C. Hussein K. Hogan W. et al. (2010 b) JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2 46 / 1 haplotype is associated with inferior survival. Leukemia 24: 105–109.
138. Tefferi A. Pardanani A. Lim K. Abdel-Wahab O. Lasho T. Patel J. et al. (2009) TET 2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia 23: 905–911.
139. Tefferi A. Vardiman J. (2008) Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 22: 14–22.
140. Teofili L. Giona F. Torti L. Cenci T. Ricerca B. Rumi C. et al. (2010) Hereditary thrombocytosis caused by MPLSer505Asn is associated with a high thrombotic risk, splenomegaly and progression to bone marrow fibrosis. Haematologica 95: 65–70.
141. Tiedt R. Hao-Shen H. Sobas M. Looser R. Dirnhofer S. Schwaller J. et al. (2008) Ratio of mutant JAK2-V617F to wild-type JAK2 determines the MPD phenotypes in transgenic mice. Blood 111: 3931–3940.
142. van der Harst P. Zhang W. Mateo Leach I. Rendon A. Verweij N. Sehmi J. et al. (2012) Seventy-five genetic loci influencing the human red blood cell. Nature 492: 369–375.
143. Vannucchi A. Masala G. Antonioli E. Chiara Susini M. Guglielmelli P. Pieri L. et al. (2009) Increased risk of lymphoid neoplasms in patients with Philadelphia chromosome-negative myeloproliferative neoplasms. Cancer Epidemiol Biomarkers Prev 18: 2068–2073.
144. Vardiman J. Harris N. Brunning R. (2002) The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 100: 2292–2302.
145. Varricchio L. Masselli E. Alfani E. Battistini A. Migliaccio G. Vannucchi A. et al. (2011) The dominant negative beta isoform of the glucocorticoid receptor is uniquely expressed in erythroid cells expanded from polycythemia vera patients. Blood 118: 425–436.
146. Vilaine M. Gourain V. Cleyrat C. Feron D. Girodon F. Morineau N. et al. (2012) Germline MPLW515R mutation in a family with isolated thrombocytosis. ASH Annual Meeting Abstracts 120: 1764.
147. Wang J. Xu Z. Liu L. Gale R. Cross N. Jones A. et al. (2013) JAK2V617F allele burden, JAK2 46 / 1 haplotype and clinical features of Chinese with myeloproliferative neoplasms. Leukemia, in press.
148. Wernig G. Mercher T. Okabe R. Levine R. Lee B. Gilliland D. (2006) Expression of JAK2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood 107: 4274–4281.
149. Wiestner A. Schlemper R. van der Maas A. Skoda R. (1998) An activating splice donor mutation in the thrombopoietin gene causes hereditary thrombocythaemia. Nat Genet 18: 49–52.
150. Zaleskas V. Krause D. Lazarides K. Patel N. Hu Y. Li S. et al. (2006) Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2V617F. PloS ONE 1: e18.
151. Zhang S. Rampal R. Manshouri T. Patel J. Mensah N. Kayserian A. et al. (2012 a) Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF 2 mutations that are associated with adverse outcome. Blood 119: 4480–4485.
152. Zhang X. Hu T. Wu Z. Kang Z. Liu W. Guan M. (2012 b) The JAK2 46 / 1 haplotype is a risk factor for myeloproliferative neoplasms in Chinese patients. Int J Hematol 96: 611–616.